1 – Lim E, Roberts L, Wicks I. Intracardiac thrombosis complicating antiphospholipid antibody syndrome. Intern Med J. 2004:34(3):135-7.
2 – Lim E, Johns J, McLaughlin S, Faragher I, Skinner I, Chao M, Gibbs P. Subsite-specific colorectal cancer in diabetic and nondiabetic patients. Cancer Epidemiol Biomarkers Prev 2005:14(6):1579-82.
3 – Rodrigues J, Lim E, McLaughlin S, Faragher I, Skinner I, Chao M, Chapman M, Gibbs P. The influence of language spoken on colorectal cancer diagnosis and management. ANZ J Surg. 2006:76:671-3.
4 – Lim E, Browning J, MacGregor D, Davis ID, Cebon JS. Antigen expression in desmoplastic melanoma: a comparison of cancer testis antigen with differentiation antigen expression. Melanoma Research. 2006:16(4):347-55.
5 – Lim E, Rosenthal M. Diagnosing cancer: changing patterns of care. Intern Med J. 2007:37(2):124-6.
6 – Lim E, Thomson BNJ , Heinz S, Chao M, Gunawardana D, Gibbs P. Optimising the approach to patients with potentially resectable liver metastases from colorectal cancer. ANZ J Surg. 2007:77(11):941-7.
7 – Lim E, Vaillant F, Wu D, Forrest N, Pal B, Hart A, et al. Aberrant luminal progenitors as a likely target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009:15(8):842-4.
8 – Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010:12(2):R21.
9 – Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE & Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010:26(17):2176-82.
10 – Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. The BH3-mimetic ABT-737 sensitizes BCL-2 expressing breast cancers to chemotherapy, implicating BCL-2 as a predictive biomarker. Proc Natl Acad Sci USA. 2011:109(8):2766-71.
11 – Ni M, Chen YW, Lim E, Bailey ST, Imai Y, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011:20(1):119-31.
12 – Lim E & Winer EP. Will preoperative trials change future clinical practice? Clinical Investigation. 2011:1(1):59-73.
13 – Lim E & Winer EP. Adjuvant chemotherapy in luminal breast cancers. Breast. 2011:20(S3):S128-31.
14 – Lim E & Winer EP. Current challenges in HER2-positive breast cancer. ASCO educational book. 2011:14-20.
15 – Lim E, Ni Min, Hazra A, Tamini R, Brown M. Elucidating the role of androgen receptors and breast cancer. Clinical Investigation. 2012:2(10):1003-11.
16 – Shen R, Zhou A, Kim E, Lim E, Habelhah H, Hahn W. IKKε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012:32(23):4756-68.
17 – Lim E & Lin NU. New insights and emerging therapies in breast cancer brain metastases. Oncology. 2012:26(7):652-9.
18 – Lim E, Metzger O, Winer EP. Natural history of hormone receptor positive breast cancer. Oncology. 2012:26(8):688-94.
19 – Ni M, Chen YW, Fei T, Li D, Lim E, Liu XS, Brown M. Amplitude modulation of androgen signaling by c- MYC. Genes Dev. 2013:27(7):734-48.
20 – Tichy J, Lim E, Anders CK. Adolescent and young adult breast cancer: A review with a focus on biology. J Natl Compr Canc Netw. 2013:11(9):1060-9.
21 – Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Fu X, Schiff R, Brown M, Brugge JS. PDEF Promotes Luminal Differentiation 1 and acts as a survival factor for ER positive breast cancer cells. Cancer Cell. 2013;23;753–67.
22- Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013:24(3):347-64.
23 – McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C, Cichowski K. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013:24(3):365-78.
24 – Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen YW, Mai JH, Shen HF, Hu DZ, Adoro S, Hu B, Song MY, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH. XBP1 promotes triple negative breast cancer by controlling the HIF1α transcriptional program. Nature. 2014:508(7494):103-7.
25 – Wang YB, Lee YM, Huang A, Lim E, Min JX, Li L, Choi C, Xiang Y, Baitsch L, Stegmeier F, Schlegel R, Gray NS, Mitchison TJ, Zhao JJ. The oncogenic protein kinase MELK is essential for mitotic progression in basal-like breast cancer cells. Elife. 2014:May20:3:e01763.
26 – Lim E, Ni M, Cao SA, Hazra A, Tamimi R, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Current Breast Cancer Reports. 2014:6(2):71-8.
27 – Lim E & Lin NU. Updates on the management of breast cancer brain metastases. Oncology. 2014:28(7):572-8.
28 – Lu G, Zhang Q, Huang Y, Song JX, Tomaino R, Ehrenberger T, Lim E, Liu WB, Bronson RT, Bowman M, Dillon DA, Gygi SP, Mills G, Richardson AL, Signoretti S, Yaffe MB, Kaelin WG Jr. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014:26(2):222-34.
29 – Lim E, Goel S, Winer EP. Chapter title: Adjuvant chemotherapy in breast cancerSpringer. NYC.
30 – Hu Y, Petit A, Ficarro S, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, Brown M, Marto JA, Livingston DM. PARP1-driven Poly-ADP-ribosylation regulates BRCA1 function in homologous recombination mediated DNA repair. Cancer Discovery. 2014;4(12):1430-47.
31 – Chia KM, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Current Oncology Reports. . 2015;17(2):427-34.
32 – Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, Mao J, McKee KK, Yurchenco PD, Mercurio AM. A Laminin 511 Matrix is regulated by TAZ and functions as the ligand for the a6Bb1 integrin to sustain breast cancer stem cells. Genes & Devt. 2015;29(1):1-6.
33 – Samanta S, Sun H, Goel HL, Pursell B, Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD, Mercurio AM. IMP3 promotes stem-like properties in Triple-Negative breast cancer by regulating SLUG. Oncogene 2015 May 18.
34 – Wang YB, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. CDK7-dependent transcriptional addiction in Triple-Negative breast cancer. Cell 2015;163(1):174-86.
35 – Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015 Oct 27;6:8746.
36 – Neupane M, Clark A, Landini S, Birkbak N, Eklund A, Lim E, Culhane A, Barry W, Schumacher S, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver D. MECP2 Is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy. Cancer Discovery. 2016:6(1):45-58.
37 – Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X targeted therapies. Frontiers Onc 2016:6:1-7.
38 – Ramchand S, Lim E, Grossmann M. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed?. Clinical Endo 6th Aug 2016.
39 – Lim E, Palmieri C, Tilley W. Renewed interest in the Progesterone Receptor in Breast Cancer. British J Cancer. 22nd Sep 2016
40 – Lim E, Tarulli G, Portman N, Hickey T, Tilley W, Palmieri C. Pushing Estrogen Receptor around in breast cancer. Endo Rel Cancer. 2016;23(12):T227-T241
41 – Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D’Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild type and mutated models of triple negative breast cancer. Cell Reports. 2016;17(9):2367-2381
42 – Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. Nov 22 2016.
43 – Portman N, Wahlroos S, Parker A, Segara D, Lim E. Endocrine therapy for breast cancer: A Renaissance. The Endocrinologist. Dec 2016.
44 – Haupt S, Vijayakumaran R, Panimaya J, Burgess A, Lim E, Haupt Y. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. Jan 17 2017.
45 – Dreijerink K, Groner AC, Vos E, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao P, Long H and Brown M. Enhancer-mediated oncogenic function of the MEN1 tumor suppressor in breast cancer. Cell Reports. 2017;18(10):2359-72
46 – Law A, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endo Rel Cancer. 2017;24(4):R123-44
47 – Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Sensitizing HR-proficient cancers to PARP inhibitors. Molecular Cellular Oncology. Mar 3 2017.
48 – Meeusen E, Lim E, Mathivanan S. Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy. Proteomics. Jul 17 2017.
49 – Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC. Cancer Immunology Research. Aug 28 2017.
50 – Robinson DH, Churilov L, Lin NU, Lim E, Seah D. Attitudes of patients with metastatic cancer towards research biopsies. APac JCO. Nov 6 2017.
51 – Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Larsson C, Eriksson P, Lehn S, Reid S, Saal LH, Anderberg C, Cortez E, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Sjölund J, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K. Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling. Nature Medicine. 2018;24(4):463-73.
52 – Hastie R, Lim E, Slukass P, Campbell L, Horne A, Ellett L, Hannan N, Brownfoot F, Kaitu’u-Lino TJ, Tong S. Vinorelbine potently induces placental cell death, does not harm fertility and is a potential oral treatment for ectopic pregnancy. EBioMedicine. 2018;29:166-76.
53 – Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol. 2018 Sep;89(3):280-296.
54 – Papachristou E, Kishore K, Holding A, Harvey K, Roumeliotis T, Chilamakuri C, Omarjee S, Chia KM, Swarbrick A, Lim E Markowetz F, Eldridge M, Siersbaek R, D’Santos C, Carroll J. Quantitative Multiplexed Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins (qPLEX-RIME) for monitoring the dynamics of chromatin-associated complexes. Nature Comms. 2018 Jun 13;9(1):2311.
55 – Cazet AS, Hui MH, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng NT, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R,Lim E, Timpson P, O’Toole S, Watkins DN, Cox TR, Samuel M, Martin M, Swarbrick A. Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer. Nature Comms. 2018 Jul 24;9(1):2897.
56 – Saunders C, Jassal S, Lim E. Breast Cancer: The Facts. Oxford University Press.. 2nd Edition 2018.
57 – Lim E, Beith J, Boyle F, de Boer R, Hui R, McCarthy N, Redfern A, Wade T, Woodward N. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:12-21.
58 – Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E McCarthy N, Redfern A, Woodward N. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on current treatment paradigm. Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:3-11.
59 – Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2018 Nov 21.
60 – Portman N, Alexandrou S, Carson EK, Wang S, Lim E, Caldon CE*. Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer. Endocr Rel Cancer. 2019:26, R15–30.
61 – Chia K,Milioli H, Portman N, Laven-Law G, Coulson R,Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocr Rel Cancer. 2019 Feb 1;26(2):251-264.
62 – Alexandrou S, George SM,Ormandy CJ, Lim E, Oakes SR,Caldon CE. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int. J. Mol. Sci. 2019, 20(3), 667.
63 – Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Summary Position Statement. Med J Aus. 2019; 211(5):224-229.
64 – Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O’Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.Breast Cancer Res. 2019,21;21(1):43.
65 – Young AR, Duarte JD, Coulson R, O’Brien M, Deb S, Lopata A, Behren A, Mathivanan S, Lim E, Meeusen E. Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes.Cancers. 2019 May 16;11(5).
66 – Chi D, Singhal H, Li L, Xiao TF, Liu WH, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, Garber J, Brown M. Estrogen Receptor Signaling is Reprogrammed During Breast Tumorigenesis.Proc Natl Acad Sci USA. 2019 May 20.
67 – Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B, Chen L, Di Bonito L, Kurtycz DFI, Lee AHS, Lim E, Ljung BM, Michelow P, Osamura RY, Pinamonti M, Sauer T, Segara D, Tse G, Vielh P, Chong PY and Schmitt F. The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytology. Acta Cytol. 2019 May 21:1-17.
68 – Chen J*, Easwaralingam N*, Warrier S, Mak C, Carson E, Ong A, Snook K, Middleton K, Parker A, Spillane A, Mann B, Lim E, Segara D. Window of Opportunity Treatment in Breast Cancer. ANZ J Surg. 26 Nov 2019.
69 – Tadesse S. Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today. 10 Dec 2019.
70 – Milioli HH, Alexandrou S, Lim E, Caldon C. Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer. 1 Feb 2020.
71 – Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, Ormandy CJ, Naylor MJ, Simpson K, Nikolic I, O’Toole S, Kaplan W, Cowley MJ, Carroll JS, Molloy M, Swarbrick A. Proteogenomic analysis of Inhibitor of Differentiation in basal-like breast cancer. Breast Cancer Research. 22(1):63, 11 Jun 2020.
72 – Light M, McFarlane T, Ives A, Shah B, Lim E, Grossmann M, Zajac JD, Cheung AS. Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male. Clinical Endo. 2020 Sep;93(3):355-7.
73 – Wu SZ, Roden D, Wang CF, Cazet A, Al-Eryani G, Harvey K, Holliday H, Murphy K, Pereira B, Bartonicek N, Hou R, Torpy J, Junankar S, Hui M, Gluch L, Beith J, Parker A, Robbins E, Segara D, Mak C, Cooper C, Warrier S, Powell J, O’Toole S, Cox T, Timpson P, Forrest A, Lim E, Liu XS, Swarbrick A. Single-cell RNA sequencing of triple-negative breast cancers reveals novel functionally distinct subclasses of stromal cells. Embo J. 2020 Oct 1;39(19).
74 – Portman N*, Milioli HH*, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Segara D, Parker A, Swarbrick A, Haupt A, Haupt Y, Tilley WD, Swarbrick A, Caldon CE*, Lim E*. Synergistic targeting of estrogen-receptor positive breast cancers by MDM2 inhibition in combination with endocrine therapy or CDK4/6 inhibition. Breast Cancer Research. 2020 Aug 12;22(1):87.
75 – Chia KM, Freelander A, Kumar S, Portman N, Lim E. Estrogen receptor positive breast cancer patient derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research. 23rd Oct 2020.
76 – De Boer R, Hui R, Lim E, Yeo B, N Zdenkowski. Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer. Asia Pacific J Clin Oncol. 2020 Nov;16 Suppl 5:3-14.
77 – Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law G, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Nature Medicine. Jan 2021.